ObsEva SA, en liquidation is a Switzerland-based company which provides services in the fields of research, development, manufacture, registration, promotion and marketing of biotechnical and pharmaceutical products.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-15	0.000010 $	-90.00%	285
26-06-12	0.000100 $	0.00%	605
26-06-11	0.000100 $	0.00%	100
26-06-10	0.000100 $	0.00%	1,517

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets Other stock markets 13:05:07 2026-06-15 EDT			5-day change	1st Jan Change
0.000010 ^USD	-90.00%		-90.00%	-90.00%

23-04-20	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
23-04-20	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT

Market Cap	4.1M 3.53M 3.25M 3.06M 5.74M 388M 5.8M 38.46M 14.98M 190M 15.39M 15.06M 658M	P/E Ratio 2021	-2.57x	P/E Ratio 2022	-0.45x
Enterprise Value	-1.3M -1.12M -1.03M -965K -1.81M -123M -1.83M -12.15M -4.73M -59.99M -4.86M -4.76M -208M	EV / Sales 2021	-	EV / Sales 2022	0.65x
Free-Float	70.16%	Yield 2021 *	-	Yield 2022	-

23-04-20	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
23-04-20	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT
23-04-11	Insider Buy: Obseva	MT
23-04-05	ObsEva SA announced that it has received CHF 0.344 million in funding	CI
23-03-31	ObsEva SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-03-30	ObsEva SA Auditor Raises 'Going Concern' Doubt	CI
23-03-22	ObsEva SA(OTCPK:OBSV.F) dropped from NASDAQ Composite Index	CI
23-03-15	ObsEva to Delist from Nasdaq, Deregister from US SEC	MT
23-03-13	ObsEva Names New CEO From May, Appoints Interim Chairman	MT
23-03-13	ObsEva Names New Interim Chairman, CEO as Reorganization Continues	MT
23-03-13	ObsEva SA Announces CEO Changes, Effective on or About May 1, 2023	CI
23-03-13	ObsEva SA Announces Executive Changes	CI
23-03-03	Top Premarket Gainers	MT

22-08-30	HC Wainwright Downgrades ObsEva to Neutral from Buy	MT
22-08-01	Canaccord Genuity Downgrades ObsEva to Hold From Buy, Adjusts Price Target to $1 From $12	MT
22-07-29	Cantor Fitzgerald Cuts ObsEva to Neutral From Overweight, Price Target to $1 From $6	MT
22-06-03	Cantor Fitzgerald Starts ObsEva at Overweight With $6 Price Target	MT
22-04-26	Canaccord Genuity Starts ObsEva at Buy With $12 Price Target	MT

ObsEva SA Stock

Stocks

OBSE.F

CH1260041939

Biotechnology & Medical Research

Valuation: ObsEva SA

Chart: ObsEva SA

Latest news : ObsEva SA

Analysts' recommendations: ObsEva SA

Press Releases: ObsEva SA

News in other languages: ObsEva SA

Quotes and Performance

Course Extremes

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

23-04-20	ObsEva Announces Change of Central Securities Depositary	GL
23-04-20	ObsEva Announces Change of Central Securities Depositary	GL
23-03-31	ObsEva Files Year End 2022 Financial Statements	GL
23-03-22	OBSEVA SA : Other Events (form 8-K)	AQ
23-03-15	ObsEva : Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange - Form 8-K	PU

23-04-20	Obseva-Aktien erhalten im Zuge von Nasdaq-Dekotierung neue ISIN-Nummer
23-04-06	Bourse Zurich: le SMI maintient ses gains à l'approche de la mi-journée
23-04-06	Bourse Zurich: ouverture en hausse avant le long week-end pascal
23-03-31	Obseva bleibt 2022 tief in den roten Zahlen
23-03-31	Obseva reste profondément en rouge en 2022, doutes sur la suite

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.05
3 years	0		0.4
5 years	0		3.58
10 years	0		20.35

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-04-05	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
23-02-27	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
23-02-22	William Brown	Free	Chief Executive Officer	250,000	0.2321%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OBSEVA SA	-90.00%	-90.00%	-	-	1.17K
ARGENX SE	-0.71%	-0.29%	+56.45%	+107.18%	54.92B
WUXI APPTEC CO., LTD.	-1.22%	+5.01%	+43.38%	+36.69%	44.31B
BIONTECH SE	-1.43%	+3.47%	-15.83%	-20.48%	22.96B
INSMED INCORPORATED	-1.99%	-3.55%	-5.97%	+377.60%	21.12B
WUXI BIOLOGICS (CAYMAN) INC.	-0.60%	+0.61%	+16.26%	-36.02%	16.31B
GENMAB A/S	-2.38%	-3.38%	+5.53%	-41.88%	15.19B
EXELIXIS, INC.	-1.70%	-1.68%	+24.79%	+172.92%	13.32B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.91%	+3.09%	+24.94%	-	12.48B
MADRIGAL PHARMACEUTICALS, INC.	+0.29%	+5.10%	+75.82%	+105.33%	11.52B
Average	-10.23%	-7.08%	+25.04%	+87.67%	21.21B
Weighted average by Cap.	-1.25%	+1.39%	+30.16%	+86.71%

	2021	2022
Net sales	-	19.64M 16.92M 15.58M 14.63M 27.47M 1.86B 27.76M 184M 71.74M 909M 73.7M 72.13M 3.15B
Net income	-58.38M -50.31M -46.33M -43.5M -81.67M -5.52B -82.53M -547M -213M -2.7B -219M -214M -9.37B	-29.88M -25.75M -23.71M -22.26M -41.8M -2.82B -42.24M -280M -109M -1.38B -112M -110M -4.79B
Net Debt	-28.08M -24.2M -22.28M -20.92M -39.27M -2.65B -39.69M -263M -103M -1.3B -105M -103M -4.5B	-5.4M -4.65M -4.28M -4.02M -7.55M -510M -7.63M -50.61M -19.72M -250M -20.25M -19.82M -866M